Clinical trials: Pancreatic Cancer Metastatic
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Pancreatic Cancer, Advanced Cancer
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- MAP-01 (NCT05802420)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Pancreatic Cancer
HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)
The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.
- Trial name
- NCT01266720
- Testing
- VEGFR1, VEGFR2, Gemcitabine
- Where
- Japan
- Volunteers
- 6 people
- Sponsor
- Fukushima Medical University
Metastatic Pancreatic Adenocarcinoma, Colorectal Cancer
TCR1020-CD8 T Cells in KRAS-mutated Cancers
This is a Phase I, open-label dose finding study to assess the safety, manufacturing feasibility, and preliminary efficacy of TCR1020-CD8 T cells in patients with KRAS-mutated cancers.
- Trial name
- NCT06707896
- Testing
- TCR1020-CD8 T cells
- Sponsor
- University of Pennsylvania
Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer
Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer
This phase II trial is studying how well saracatinib works in treating patients with previously treated metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
- Trial name
- NCT00735917
- Testing
- saracatinib, pharmacogenomic studies, pharmacological study
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Pancreas Cancer
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
The purpose of this research is to determine the benefit of pemigatinib in patients with advanced metastatic or surgically unresectable adenosquamous carcinoma of the pancreas who have progressed on previous therapy.
- Trial name
- NCT05216120
- Testing
- Pemigatinib 4.5 MG
- Where
- United States
- Sponsor
- HonorHealth Research Institute
Adenocarcinoma, Adenocystic Carcinoma
The Registry of Oncology Outcomes Associated With Testing and Treatment
This study is to collect and validate regulatory-grade real-world data (RWD) in oncology using the novel, Master Observational Trial construct. This data can be then used in real-world evidence (RWE) generation.
- Conditions
- Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer
- Trial name
- ROOT (NCT04028479)
- Testing
- Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P)
- Where
- 2 sites in United States
- Volunteers
- 167 people
- Sponsor
- Taproot Health
Pancreatic Cancer, Breast Cancer
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Study of NGM831 as Monotherapy and in Combination with Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
- Conditions
- Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT05215574
- Testing
- NGM831, NGM831 plus pembrolizumab (KEYTRUDA®), NGM831 and NGM438 plus pembrolizumab (KEYTRUDA®)
- Where
- 9 sites in United States
- Volunteers
- 130 people
- Sponsor
- NGM Biopharmaceuticals, Inc
Locally Advanced or Metastatic Pancreatic Cancer
SLOG vs mFOLFIRINOX as the First-line Treatment in Locally Advanced Uncresectable or Metastatic Pancreatic Cancer
A randomized phase II study to compare the efficacy and safety of SLOG or mFOLFIRINOX as a first-line treatment for patients with locally advanced and metastatic pancreatic cancer.
- Trial name
- Pancreas (NCT03443492)
- Testing
- S-1, Leucovorin(oral ), Gemcitabine
- Where
- Taiwan
- Volunteers
- 130 people
- Sponsor
- National Health Research Institutes, Taiwan
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Pancreatic Cancer, Colorectal Cancer
Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers
This is a Phase I/Ib study in which the safety of the combination therapy of RMC-4630 and LY3214996 in the treatment of KRAS mutant cancers will be studied.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, KRAS Mutation-Related Tumors
- Trial name
- SHERPA (NCT04916236)
- Testing
- RMC-4630, LY3214996
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma
Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer
This pilot phase IIb trial studies how well pembrolizumab and CXCR4 antagonist BL-8040 work in treating patients with pancreatic cancer that has spread to other places.
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v6 and v7
- Trial name
- NCT02907099
- Testing
- CXCR4 Antagonist BL-8040, Pembrolizumab, Pharmacological Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer
The purpose of this study is to investigate the effect of very low dose decitabine combinate with gemcitabine in the first-line treatment of locally advanced, unresectable and metastatic pancreatic cancer.
- Trial name
- SLOWDOSE001 (NCT02685228)
- Testing
- Decitabine, Gemcitabine
- Volunteers
- 20 people
- Sponsor
- The First Hospital of Jilin University
Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
FMT Plus SHR-1701 With Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
This is a prospective, single-center, randomized, open-label, two-arm Phase II clinical trial design to evaluate the feasibility, safety and preliminary efficacy of combining fecal Fecal Microbiota Transplantation （FMT） Combined…
- Trial name
- NCT07845565
- Testing
- FMT+Chemotherapy+Immunotherapy, Chemotherapy+Immunotherapy
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pancreas Cancer
A Single-center Clinical Study to Evaluate the Safety and Efficacy of Autologous Bone Marrow-derived DCs(CellgramDC-WT1) and Immune Checkpoint Inhibitors in Patients With Metastatic Pancreatic Cancer Who Have Failed First-line or More Standard Chemotherapy
To evaluate the safety and effectiveness of immune cell therapy using autologous bone marrow-derived dendritic cells and immune checkpoint inhibitors in patients with metastatic pancreatic cancer who have failed at least one…
- Trial name
- DICI_PC (NCT06172634)
- Testing
- dentritic cell infusion and immunecheckpoint inhibitor
- Volunteers
- 10 people
- Sponsor
- Soonchunhyang University Hospital
Gastric Cancer, Gastroesophageal-junction Cancer
Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
This is a Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects with Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal…
- Conditions
- Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer, Pancreatic Cancer
- Trial name
- NCT05539430
- Testing
- LB1908
- Where
- 9 sites in United States
- Volunteers
- 56 people
- Sponsor
- Legend Biotech USA Inc
Pancreas Neoplasms
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
The goal of this clinical trial is to estimate the antitumor response of mFOLFIRINOX + Dostarlimab + oral HD vitamin D3 in patients with non-pretreated histologically confirmed metastatic Stage IV adenocarcinoma of the pancreas.
- Trial name
- DOVIPA (NCT06757244)
- Testing
- Dostarlimab, Vitamin D3 (Cholecalciferol), mFOLFIRINOX Treatment Regimen
- Where
- 5 sites in France
- Volunteers
- 35 people
- Sponsor
- Hopital Foch
Metastatic Pancreatic Adenocarcinoma
Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer
In the current study it is examined whether patients with good risk factors (age <75 years, total serum bilirubin < 1,5xULN, no history of cardiovascular diseases) treated with gemcitabine and erlotinib who developed skin rash of…
- Trial name
- ML22774 (NCT01729481)
- Testing
- Gemcitabine, Erlotinib, Oxaliplatin
- Where
- Germany
- Volunteers
- 150 people
- Sponsor
- Ludwig-Maximilians - University of Munich
Metastatic Pancreatic Cancer
Spleen Irradiation With Nanoliposomal Irinotecan Plus 5-FU and Leucovorin in Metastatic Pancreatic Adenocarcinoma
Splenomegaly is common in advanced pancreatic ductal adenocarcinoma (PDAC). The spleen is an important source of immune suppressive cells and phagocytic cells and may mediate the accumulation of liposomal drugs and…
- Trial name
- SINAI (NCT05363007)
- Testing
- nanoliposomal irinotecan, spleen irradiation
- Where
- 2 sites in Taiwan
- Volunteers
- 60 people
- Sponsor
- National Taiwan University Hospital
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
Liquid Biopsy and Pancreas Cancer: Detection of AXL(+) CTCs (CTC-AXL-PANC)
In solid cancers, some more aggressive tumor cells actively detach from the primary lesion and then travel through the circulating compartment to reach distant organs and form micro-metastases.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer, Circulating Tumor Cell
- Trial name
- CTC-AXL-PANC (NCT05346536)
- Testing
- Detection of circulating tumor cells expressing Axl: CTC-AXL(+)
- Where
- France
- Volunteers
- 63 people
- Sponsor
- University Hospital, Montpellier